Bringing a new drug to the market is a massive undertaking, but conventional preclinical models often fail to predict human response. This failure is a major reason why 90% of drugs that pass the preclinical stage ultimately fail during human trials. However, Organ-on-a-Chip technology offers a paradigm shift in drug development.
Even with tremendous improvements in the study of human biology — some caused by the phenomenon Moore’s Law describes — the cost of advancing a compound through clinical trials to FDA approval continues to skyrocket. “Eroom’s Law”, coined by Economist Jack Scannell as a cheeky reversal of Moore’s Law, observes that drug development is only slowing down and getting more expensive.
Explore compelling evidence that suggests Organ-on-a-Chip technology offers a far more reliable means of predicting drug toxicity than traditional animal models.
The drug development industry recognizes the importance of predictive validity, but Jack Scannell, the author of Eroom’s law, and a team of experts argue it is even more crucial than most believe it to be.
For centuries, animal studies have been the cornerstone of preclinical research, offering invaluable insights into human biology and disease mechanisms. However, as science progresses, so do our tools. Enter Organ-Chips, a cutting-edge technology poised to reshape the landscape of biomedical research.
In the complex landscape of drug discovery and development, the need for more predictive, human-relevant models is paramount. Many researchers are turning to advanced in vitro models like Organ-Chips for deeper insights into disease mechanisms and more accurate assessments of drug safety and efficacy.
This website uses cookies to ensure you get the best experience on our website. Learn more
